• Fri news: Pfizer’s $1B Chinese commitment. RFK Jr. and pharma. Eisai dials back Leqembi forecast. US diabetes burden increase. JNJ gets Varipulse approval. See more on our front page

Sarepta pulls plug on Duchenne exon-skipping drug

cafead

Administrator
Staff member
  • cafead   Nov 07, 2024 at 11:22: AM
via Sarepta Therapeutics has decided not to continue the development of vesleteplirsen, a follow-up to its Duchenne muscular dystrophy (DMD) therapy Exondys 51.

article source